Supported by an educational grant from Daiichi Sanyko

Click on the link to complete the pre-assessment questions before the session begin: https://mli.link/sohoamlpre

SESSION III: ACUTE MYELOID LEUKEMIA

Session Chairs: Farhad Ravandi, MD and Andrew Wei, MBBS, PhD

Menin Inhibitors in NPM1-Mutated and KMT2Ar AML: Combinations and Resistance Mechanisms | Ghayas C. Issa, MD | MD Anderson Cancer Center, Houston, Texas, USA

How to Best Incorporate FLT3 Inhibitors in the Management of FLT3 Mutated AML | Alexander E. Perl, MD | University of Pennsylvania, Philadelphia, Pennsylvania, USA

IDH Inhibitor Combination Strategies in IDH Mutated AML | Courtney D. DiNardo, MD, MSCE | MD Anderson Cancer Center, Houston, Texas, USA

DEBATE: The Best Strategy Using Lower Intensity Regimens is Concomitant Therapy | Naval Daver, MD | MD Anderson Cancer Center, Houston, Texas, USA

DEBATE: The Best Strategy Using Lower Intensity Regimens is Sequential Use of Agents | Uma M. Borate, MD, MS | Ohio State University, Columbus, Ohio, USA

Use of MRD to Guide Therapeutic Decision Making | Andrew Wei, MBBS, PhD | Peter MacCallum Cancer Centre, Melbourne, Australia

Novel Strategies in High-Risk AML- Focus on Immune-Based Strategies | David A. Sallman, MD | H. Lee Moffitt Cancer Center, Tampa, Florida, USA

Improving Risk Stratification in AML and Potential Role for AI? | Amin Turki, MD, PhD | University Hospitals Essen, Essen, German

Oral Abstract | AML-789: Ziftomenib in Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia (AML): Phase 1b/2 Results From the Pivotal KOMET-001 Study | Ghayas C. Issa, MD | MD Anderson Cancer Center, Houston, Texas, USA